Laboratory for Gynecologic Oncology, Women's Hospital/Department of Biomedicine, University of Basel, Switzerland.
Ann N Y Acad Sci. 2010 Sep;1205:17-22. doi: 10.1111/j.1749-6632.2010.05659.x.
Umbilical cord blood (UCB) is a valuable alternative source of hematopoietic stem cells (HSCs). It has unique advantages of easy procurement, absence of risk to donors, low risk of transmitting infections, immediate availability, greater tolerance of human leukocyte antigen (HLA) disparity, and lower incidence of inducing severe graft-versus-host disease (GVHD). In the last several years, these features of UCB permit the field of UCB transplantation (UCBT) to move at a faster pace for both children and adults with malignancies and nonmalignancies. However, new strategies and novel developments are expected to improve engraftment and reconstitution, and to enable in utero transplantation for early therapy, as well as to allow the therapy for a wide spectrum of human diseases.
脐带血（UCB）是一种有价值的造血干细胞（HSCs）替代来源。它具有易于采集、供者无风险、感染传播风险低、可立即获得、对人类白细胞抗原（HLA）差异的耐受性更高、诱导严重移植物抗宿主病（GVHD）的发生率更低等独特优势。在过去几年中，这些 UCB 的特点使得 UCB 移植（UCBT）领域在儿童和成人的恶性和非恶性疾病中都能更快地发展。然而，新的策略和新的发展有望改善植入和重建，实现宫内移植以进行早期治疗，并为广泛的人类疾病提供治疗。
